Orchid Pharma has informed that the company received the Establishment Inspection Report (EIR) from USFDA based on the successful inspection closure for the formulation manufacturing facility located at Irungattukottai, Sriperumbudur, Kancheepuram District, India. The facility was inspected by USFDA in the month of May 2015.
The above information is a part of company’s filings submitted to BSE.